Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Organigram (OGI) to C$3 from C$4.25 and keeps a Buy rating on ...

Biotechnology has quietly revolutionized various aspects of human life, far beyond the confines of the lab. Though ...

The proposed Passyunk Connection would allow users to connect from Gray’s Ferry Avenue to Passyunk Avenue on ... planned on ...

The "Pharmaceutical R&D Outsourcing Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Pharmaceutical R&D Outsourcing Market was valued at USD 84.01 ...

What’s in and out for skin in 2025? Leading dermatologists share what’s trending in skin care this year, plus their most-recommended products to try.

San Diego was detained by officers from the National Crime Agency, supported by Counter Terrorism Policing and North Wales Police, at a property in a rural area next to woodland in Conwy, on November ...

An icon of a desk calendar. An icon of a circle with a diagonal line across. An icon of a block arrow pointing to the right. An icon of a paper envelope. An icon of the Facebook "f" mark.

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

All products on this page have been selected by our editorial team, however we may make commission on some products. The grey sweatshirt was first introduced as part of sportswear in the 1920s, when ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...